Utility of 3-year torso computed tomography and head imaging in asymptomatic patients with high-risk melanoma

Melanoma Research

Volumn 21, Issue 4, 2011, Pages 364-369

  Derose, Erin R ^a   Pleet, Alexander ^a   Wang, Wei ^a   Seery, Virginia J ^a   Lee, Mee Young ^a   Renzi, Sharon ^a   Sullivan, Ryan J ^a   Atkins, Michael B ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

computed tomography scan; cost benefit analysis; imaging; melanoma

Indexed keywords

ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; ASYMPTOMATIC DISEASE; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE FREE INTERVAL; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SYMPTOM; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BOSTON; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; HEAD AND NECK NEOPLASMS; HOSPITAL COSTS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79960706451     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3283471086     Document Type: Review

References (19)

1. National Cancer Institute Surveillance Epidemiology and End Results 2010.
2. Balch CM, Soong SJ, Atkins MB, Buzaid AC, Cascinelli A, Coit DG, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 2004; 54:131-149. quiz 182-184.
3. Balch CM, Houghton A Jr, Sober A, Soong SJ, Atkins MB, Thompson JF. Cutaneous melanoma. 5th ed. Missouri: Quality Medical Publishing, Inc.; 2009. pp. 565-572.
4. Aloia TA, Gershenwald JE, Andtbacka RH, Johnson MM, Schacherer CW, Ng CS, et al. Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma. J Clin Oncol 2006; 24:2858-2865. (Pubitemid 46630586)
5. Miranda EP, Gertner M, Wall J, Grace E, Kashani-Sabet M, Allen R, et al. Routine imaging of asymptomatic melanoma patients with metastasis to sentinel lymph nodes rarely identifies systemic disease. Arch Surg 2004; 139:831-836. discussion 836-837.
6. Gold JS, Jaques DP, Busam KJ, Brady MS, Coit DG. Yield and predictors of radiologic studies for identifying distant metastases in melanoma patients with a positive sentinel lymph node biopsy. Ann Surg Oncol 2007; 14:2133-2140. (Pubitemid 46988267)
7. Hofmann U, Szedlak M, Rittgen W, Jung EG, Schadendorf D. Primary staging and follow-up in melanoma patients-monocenter evaluation of methods, costs and patient survival. Br J Cancer 2002; 87:151-157.
8. Buzaid AC, Tinoco L, Ross MI, Legha SS, Benjamin RS. Role of computed tomography in the staging of patients with local-regional metastases of melanoma. J Clin Oncol 1995; 13:2104-2108.
9. Kuvshinoff BW, Kurtz C, Coit DG. Computed tomography in evaluation of patients with stage III melanoma. Ann Surg Oncol 1997; 4:252-258. (Pubitemid 127725252)
10. Francken AB, Shaw HM, Accortt NA, Soong SJ, Hoekstra HJ, Thompson JF. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol 2007; 14:1924-1933. (Pubitemid 46870937)
11. Romano E, Scordo M, Dusza SW, Coit DG, Chapman PB. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J of Clin Oncol 2010; 28:3042-3047
12. National Comprehensive Cancer Network (NCCN) guidelines, 2010.
13. Johnson TM, Fader DJ, Chang AE, Yahanda A, Smith JW II, Hamlet KR, et al. Computed tomography in staging of patients with melanoma metastatic to the regional nodes. Ann Surg Oncol 1997; 4:396-402. (Pubitemid 127725514)
14. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14:7-17. (Pubitemid 26019991)
15. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000; 18:2444-2458. (Pubitemid 30415832)
16. Francken AB, Accortt NA, Shaw HM, Colman MH, Wiener M, Soong SJ, et al. Follow-up schedules after treatment for malignant melanoma. Br J Surg 2008; 95:1401-1407.
17. Shumate CR, Urist MM, Maddox WA. Melanoma recurrence surveillance. Patient or physician based? Ann Surg 1995; 221:566-569. discussion 569-571.
18. Weiss M, Loprinzi CL, Creagan ET, Dalton RJ, Novotny P, O'Fallon JR. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA 1995; 274:1703-1705.
19. Meyers MO, Yeh JJ, Frank J, Long P, Deal AM, Amos KD, et al. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging. Ann Surg Oncol 2009; 16:941-947.